The following trials provide information to treat various types of respiratory and inflammatory diseases, both for ongoing and completed clinical trials. For more information on both of these therapy areas please click here.
- collapse Estimating the Use of Resources and the Costs of Treating Patients With Asthma in the Autonomous Community of Valencia
- collapse A Study for the Assessment of the Words Used by Patients and Physicians to Express the Symptoms of Chronic Obstructive Pulmonary Disease (COPD)
- collapse Utilization of fixed combination (budesonide/formoterol and salmeterol/fluticasone and beclomethasone/formoterol) in treatment of asthma patients in real life condition in Czech Republic (UFO)
- collapse Efficacy and Safety Study of Symbicort Turbuhaler Versus Oxis Turbuhaler in Chronic Obstructive Pulmonary Disease (COPD) Patients
- collapse Real Life Effectiveness in Patients With Not Optimally Controlled Asthma
- collapse A comparison of Symbicort SMART (160/4.5µg) and Symbicort Turbuhaler 160/4.5 µg, plus terbutaline Turbuhaler 0.4 mg as needed, for treatment of asthma - a 12-month, randomized, double-blind, parallel group, active-controlled, multinational phase III study in asthmatic patients from 16 years
- collapse Effect of a Pharmaceutical Intervention on the Level of Control of the Asthmatic Patient
- collapse A 12-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multinational, Phase IIb Study to Evaluate the Efficacy and Safety of 60mg AZD9668 Administered Orally twice daily to subjects with Chronic Obstructive Pulmonary Disease (COPD) on treatment with Budesonide/Formoterol
- collapse Effect on Structural Changes in Airways, Measured by MSCT, of Twice Daily 60mg AZD9668 for 12 Weeks in Chronic Obstructive Pulmonary Disease (COPD) Patients
- collapse A 12-week, randomised, double-blind, placebo-controlled, parallel group, multinational, phase IIb dose range finding study to evaluate the efficacy and safety of AZD9668 administered orally at 3 dose levels to patients with Chronic Obstructive Pulmonary Disease (COPD) on treatment with tiotropium
